領航醫藥生物科技(00399.HK)全年公司擁有人應占虧損減少至2.22億港元
格隆匯 6 月 29日丨領航醫藥生物科技(00399.HK)發佈公告,截至2020年3月31日止年度,公司實現收益1458萬港元,同比下降21.57%;公司股東應占虧損2.22億港元;每股基本虧損14.42港仙,不派息。
本財政年度,集團的收益減少主要由於本財政年度美容設備及產品貿易分部的業務減少。於本財政年度,公司擁有人應占虧損減少至2.22億港元,較上一財政年度虧損減少3781萬港元。虧損減少主要由於於聯營公司的權益及可換股債券投資已全數於本財務年度出售,因此於聯營公司的權益並無減值及可換股債券投資的公平值變動虧損減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.